Clinical trial NCT05923788: T1 Mapping in Fabry Disease
Official title: T1 Mapping in Diagnosis and Follow up of Fabry Disease
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Fabry Disease
Keywords: Fabry Disease
T1 mapping
functional MRI
Fabry nephropathy
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2023-06-28
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Fabry disease (OMIM-301500, FD) is a lysosomal storage disease with X-linked inheritance secondary to mutations in the α-galactosidase A gene (GLA), which cause absence or decreased activity of the lysosomal hydrolase a-galactosidase A (a-gal A). The accumulation of globotriaosylceramide (Gb3) leads to multiple organs dysfunction, especially in three key organs: kidney, heart and cerebrovascular system. Progressive nephropathy is one of the main features of Fabry disease and is marked by an insidious development. The investigators are facing different current challenges about treatment initiation in non-classic phenotype patients, optimal dose after treatment initiation, and treatments monitoring in Fabry nephropathy. That is even more important that the enzyme replacement therapy is expensive and a lifelong commitment.

Functional magnetic resonance imaging (MRI) is now able to provide T1 mapping sequence. In Fabry disease, T1 mapping is currently used to assess the degree of myocardial involvement. The MRI for assessement of Fabry Cardiomyopathy is now recommended by the 2022 national diagnostic and care protocol (PNDS) in France. However there is no data about T1 mapping values in kidney in Fabry's disease The main Objective is to describe renal performance through multi-parametric MRI in Fabry nephropathy and the primary outcome will be the quantification of renal T1 in Fabry patients.


Eligibility criteria: Inclusion Criteria:

* Patient with confirmed Fabry disease Or Control patients: Patients undergoing renal functional exploration for a reason other than Fabry disease, amyloidosis, hemochromatosis
* Adult patient
* Patient informed of the study and agree to participate
* Patient affiliated to a social security or beneficiaries of a similar scheme

Exclusion Criteria:

* Weight \> 130 kg
* kidney transplant,
* polycystic kidney disease,
* Pregnant, parturient or breastfeeding
* Contraindications to MRI
* Subject participating in another research including an exclusion period still in progress at inclusion
* Persons deprived of their liberty by a judicial or administrative decision,
* Adults subject to a legal protection measure (safeguard measure, guardianship, curators)

Primary outcomes:
measure: T1 value measured
timeFrame: Day 1
Secondary outcomes:
measure: Apparent diffusion coefficient (ADC) coefficient values
timeFrame: Day 1
measure: R2* coefficient values
timeFrame: Day 1
measure: T2 value measured
timeFrame: Day 1
measure: T1 mapping measurement Fabry disease
timeFrame: Day 1
measure: In Fabry disease patients, evaluation of the association between the T1 values measured and concentration of plasma globotriaosylsphingosine (LysoGb3)
timeFrame: Day 1
measure: In Fabry disease patients, evaluation of the association between glomerular filtration rate and ADC value measured
timeFrame: Day 1
measure: In Fabry disease patients, evaluation of the association between glomerular filtration rate and R2* value measured
timeFrame: Day 1
measure: In Fabry disease patients, evaluation of the association between glomerular filtration rate and T2 value measured
timeFrame: Day 1
measure: In Fabry disease patients, evaluation of the association between proteinuria and ADC value measured
timeFrame: Day 1
measure: In Fabry disease patients, evaluation of the association between proteinuria and R2* value measured
timeFrame: Day 1
measure: In Fabry disease patients, evaluation of the association between proteinuria and T2 value measured
timeFrame: Day 1
Other outcomes:
Locations:
city: Bron
country: France
facility: Hopital Femme Mère Enfant
city: Lyon
country: France
facility: Hopital Edouard Herriot
Study officials:
References: